Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“The Phase 2b REZILIENT1 study of zipalertinib (CLN-081/TAS6417) met its primary endpoint of response rate in patients with EGFR exon 20 insertion mutation NSCLC.”